首頁 > 市場調查報告書 > 醫療設備

整形外科美容整形

市場調查報告書

商品編碼

1454728

美容注射市場- 按類型（肉毒桿菌毒素、真皮填充劑（產品（透明質酸、羥基磷灰石鈣）、應用（臉部提升、除皺）））、性別、年齡層、最終用戶和預測2024 - 2032

Aesthetic Injectables Market - By Type (Botulinum Toxin, Dermal Fillers (Product (Hyaluronic Acid, Calcium Hydroxyapatite), Application (Face Lift, Wrinkle Reduction))), Gender, Age Group, End-user & Forecast2024 - 2032

出版日期: 2024年02月06日 | 出版商:

Global Market Insights Inc. | 英文 240 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於注射技術的不斷進步以及對現有治療方法的認知不斷增強，2024 年至 2032 年全球美容注射市場規模將以 10.2% 的CAGR成長。不斷湧現的創新正在為解決從皺紋到臉部體積損失等各種美容問題提供更安全、更有效的解決方案。注射治療的多功能性可滿足廣泛的美感需求，有助於吸引更廣泛的消費者群體。隨著消費者越來越了解其好處和可能性，市場將顯著擴大。例如，2024 年 2 月，Merz Aesthetics 推出了 RADIESSE 的新用途，作為美容注射劑，旨在增強肩部區域的中度至重度皺紋。

美容注射劑產業根據類型、性別、年齡層、最終用戶和地區進行分類。

就類型而言，由於對非侵入性美容手術的需求激增，真皮填充劑領域的市場價值在 2024 年至 2032 年間將實現 10.7% 的CAGR。對年輕外表的強烈渴望和人口老化的不斷成長正在推動注射技術的進步。臉部除皺注射越來越受歡迎，因為它們提供了傳統手術的便利替代方案，吸引了那些尋求無需停機就能恢復活力的人。隨著全球越來越多的人選擇這些手術，該細分市場將持續成長。

根據最終用戶的情況，到2032 年，醫院在美容注射劑行業將取得相當大的立足點。這是由於對在醫院環境中進行的微創美容手術的需求不斷成長所推動的，患者可以從先進的醫療設施和專家護理中受益。此外，醫院對安全協議和無菌環境的高度重視與對病人安全和滿意度的日益重視是一致的。隨著越來越多的人尋求肉毒桿菌和皮膚填充劑等治療方法，醫院將成為主要提供者，進一步推動產品需求。

受多種因素的推動，包括中國和印度可支配收入的增加，以及美容手術在這兩個國家變得越來越流行，亞太地區美容注射劑市場規模從 2024 年到 2032 年將呈現 12.2% 的CAGR。人們對美容和護膚意識的不斷提高，加上技術的進步和人口老化的加劇，都刺激了對注射療程的需求。整體而言，亞太地區動態的市場格局和人口趨勢將有利於產業成長。

產業生態系統分析
產業影響力
- 成長動力
  - 老年人口不斷增加
  - 已開發國家對臉部美學的認知與關注不斷提高
  - 對微創美容手術的需求不斷增加
  - 已開發國家的專業人員和設施數量不斷增加
- 產業陷阱與挑戰
  - 與美容注射相關的高成本
  - 與這些程序相關的副作用
成長潛力分析
監管環境
技術景觀
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按類型，2018 - 2032

主要趨勢
肉毒桿菌毒素
- A型肉毒桿菌毒素
- 肉毒桿菌B
真皮填充劑
- 依產品類型
  - 玻尿酸
  - 羥基磷灰石鈣
  - 聚-L-乳酸
  - 聚甲基丙烯酸甲酯微球（PMMA）
  - 膠原
  - 脂肪填充劑
  - 其他真皮填充劑
- 按申請
  - 臉部提升
  - 臉部矯正
  - 減少皺紋
  - 痤瘡疤痕
  - 脂肪萎縮
  - 豐唇
  - 髖關節增強術
  - 豐胸
  - 手部年輕化
  - 陰莖增大
  - 眼瞼整形術
  - 頸部和下巴提升術
  - 其他應用

第 6 章：市場估計與預測：按性別分類，2018 年 - 2032 年

主要趨勢
女性
男性

第 7 章：市場估計與預測：按年齡分類，2018 - 2032

主要趨勢
15 - 30 次
31 - 40
41 - 50
51 - 60
> 60

第 8 章：市場估計與預測：按最終用戶分類，2018 年 - 2032 年

主要趨勢
醫院
皮膚科診所
其他最終用戶

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc (Allergan Plc.)
Bio-Med Private Limited
Bioxis Pharmaceuticals
Cytophil, Inc.
Galderma S.A.
Ipsen SA
Laboratories Vivacy SAS
Merz Pharma GmbH & Co. KGaA.
Mesoestetic
Sinclair Pharma (Huadong Medicine Co., Ltd)
Suneva Medical, Inc
Teoxane Laboratories

簡介目錄

Product Code: 8040

Global Aesthetic Injectables Market size will grow at 10.2% CAGR from 2024 to 2032, due to the ongoing advancements in injectable technologies coupled with the growing awareness of available treatments. Rising innovations are offering safer and more effective solutions for addressing various cosmetic concerns, from wrinkles to facial volume loss. The versatility of injectable treatments for catering to a wide range of aesthetic needs is helping attract a broader consumer base. With consumers becoming more informed about the benefits and possibilities, the market will expand significantly. For instance, in February 2024, Merz Aesthetics introduced a new use for RADIESSE as an aesthetic injectable designed to enhance moderate to severe wrinkles in the decollete region.

The aesthetic injectables industry is classified on the basis of type, gender, age group, end-user, and region.

In terms of type, the market value from the dermal fillers segment will secure a 10.7% CAGR between 2024 and 2032, attributed to the surge in the demand for non-invasive cosmetic procedures. The strong desire for youthful appearance and the growing aging population is driving advancements in injectable technologies. Face lift injectables have grown popular as they offer a convenient alternative to traditional surgery, appealing to those seeking rejuvenation without the downtime. With an increasing number of individuals opting for these procedures worldwide, the segment will witness sustained growth.

Based on the end-user, the hospital segment in the aesthetic injectables industry will achieve a considerable foothold by 2032. This is propelled by the growing demand for minimally invasive cosmetic procedures performed in hospital settings, where patients benefit from advanced medical facilities and expert care. Additionally, the strong emphasis of hospitals on safety protocols and sterile environments aligns with the increasing emphasis on patient safety and satisfaction. As more individuals seek treatments like Botox and dermal fillers, hospitals will become the primary providers, further driving the product demand.

Asia Pacific aesthetic injectables market size will exhibit a 12.2% CAGR from 2024 to 2032, fueled by several factors, including the increasing disposable incomes in China and India, where aesthetic procedures are becoming more popular. The rising awareness of beauty and skincare coupled with technological advancements and the growing aging population are fueling the demand for injectable treatments. Overall, the presence of dynamic market landscape and demographic trends in Asia Pacific will prove favorable for the industry growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 Data collection
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing elderly population
  - 3.2.1.2 Rising awareness and focus about facial aesthetics in developed countries
  - 3.2.1.3 Increasing demand for minimally invasive cosmetic procedures
  - 3.2.1.4 Increasing number of professionals and facilities in developed countries
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 High cost associated with aesthetic injectables
  - 3.2.2.2 Side effects associated with these procedures
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Botulinum toxin
- 5.2.1 Botulinum toxin A
- 5.2.2 Botulinum toxin B
5.3 Dermal fillers
- 5.3.1 By product type
  - 5.3.1.1 Hyaluronic acid
  - 5.3.1.2 Calcium hydroxyapatite
  - 5.3.1.3 Poly-L-lactic acid
  - 5.3.1.4 Polymethyl-methacrylate microspheres (PMMA)
  - 5.3.1.5 Collagen
  - 5.3.1.6 Fat fillers
  - 5.3.1.7 Other dermal fillers
- 5.3.2 By application
  - 5.3.2.1 Face lift
  - 5.3.2.2 Facial correction
  - 5.3.2.3 Wrinkles reduction
  - 5.3.2.4 Acne scar
  - 5.3.2.5 Lipoatrophy
  - 5.3.2.6 Lip enhancement
  - 5.3.2.7 Hip augmentation
  - 5.3.2.8 Breast enhancement
  - 5.3.2.9 Hand rejuvenation
  - 5.3.2.10 Penis enlargement
  - 5.3.2.11 Blepharoplasty
  - 5.3.2.12 Neck & chin lift
  - 5.3.2.13 Other applications

Chapter 6 Market Estimates and Forecast, By Gender, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Female
6.3 Male

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 15 - 30
7.3 31 - 40
7.4 41 - 50
7.5 51 - 60
7.6 > 60

Chapter 8 Market Estimates and Forecast, By End-User, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospitals
8.3 Dermatology clinics
8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of Middle East and Africa